81.6B, trading at HK$57.50 on the HKSE. This SniperIQ fundamentals page covers Jiangsu Hengrui Pharmaceuticals's valuation (P/E 44.3x, P/B 5.7x), profitability (net margin 24.9%), revenue (HK5.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
81.6B
P/E (TTM)44.3x
Net Margin24.9%
Revenue (FY25)HK
5.2B

Full research coverage

Frequently Asked Questions

What is Jiangsu Hengrui Pharmaceuticals's market cap?

Jiangsu Hengrui Pharmaceuticals (1276) has a market capitalization of approximately HK

81.6B, trading at HK$57.50 on the HKSE. Market cap moves with the live share price.

What is Jiangsu Hengrui Pharmaceuticals's P/E ratio?

Jiangsu Hengrui Pharmaceuticals's trailing twelve-month P/E ratio is 44.3x, with a price-to-book (P/B) of 5.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Jiangsu Hengrui Pharmaceuticals?

Jiangsu Hengrui Pharmaceuticals runs a net profit margin of 24.9%, a gross margin of 86.2%, and an operating margin of 27.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Jiangsu Hengrui Pharmaceuticals generate?

Jiangsu Hengrui Pharmaceuticals reported revenue of HK

5.2B for fiscal year 2025, with net income of HK$8.6B and earnings per share (EPS) of 1.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Jiangsu Hengrui Pharmaceuticals pay a dividend?

Jiangsu Hengrui Pharmaceuticals offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Jiangsu Hengrui Pharmaceuticals financially healthy?

Jiangsu Hengrui Pharmaceuticals carries a debt-to-equity ratio of 0.00x and a current ratio of 9.23x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Jiangsu Hengrui Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jiangsu Hengrui Pharmaceuticals (1276) the key facts are: market cap HK

81.6B, P/E 44.3x, revenue HK5.2B, 52-week range 51.3-95.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Jiangsu Hengrui Pharmaceuticals's full fundamentals live

Get Jiangsu Hengrui Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.